The power of asynchronous advisory
The Challenge
A life science company franchise faced the challenge of launching multiple products over four years while keeping up with the evolving therapeutic landscape and healthcare provider (HCP) perceptions of competitor products. They needed to enhance live advisory boards and create opportunities for regional engagement.
The Solution
ClinicalMind recommended using the Asynchronous Advisory Suite to conduct a series of surveys. This approach aimed to identify changes in HCP practices, challenges in accessing new therapies, and varied treatment approaches to guide future commercial strategy and tactics.
The Implementation
Conducted 3 virtual advisory board meetings, extending interactions with key customers beyond live meetings.
Established a Rapid Feedback Committee with 95 advisors, achieving a 90% participation rate in 6 out of 8 annual surveys.
Developed top-line and full executive summary reports for each advisory activity.
Set up pre-meeting surveys for 10 in-person regional advisory boards, sharing aggregated data to foster discussion and solution-oriented interaction.
The Results
The Asynchronous Advisory Suite provided crucial information during the rolling launch, uncovering payer barriers and allowing for quick course correction on commercial strategy. Survey data informed future advisory meetings, enabling the client to focus on emerging issues. The marketing manager noted that ClinicalMind made launching activities seamless, handling all details and providing a turnkey process.
About Asynchronous Advisory Suite
ClinicalMind’s asynchronous advisory site is a game changer for life-science companies navigating the rapidly evolving and competitive therapeutics market. This powerful online toolkit provides virtual engagement with healthcare professionals, giving crucial feedback and allowing for informed decisions and quick course correction. The suite is designed to be turnkey and seamless, making the perfect solution for companies looking to stay ahead in the market.